drugset / Trial / NCT03559764
Study of BCMA CAR-T in Multiple Myeloma
SequentialOpen-labelTreatment
Summary
This is a single centre、single arm、open-label，to investigate the safety and efficacy of anti-BCMA CAR T cells in patients with Relapsed and Refractory multiple myeloma.
Timeline
- Start
- 2018-06
- Primary completion
- 2020-02
- Completion
- 2020-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-BCMA CAR T cells | Cell therapy | 500000 cells/kg | — |
| Subject | Anti-BCMA CAR T cells | Cell therapy | 6e+06 cells/kg | — |